Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China's KBP Closes $76 Million A Round; Opens Philadelphia Global Headquarters

publication date: Jan 5, 2018

KBP Biosciences, a Jinan clinical-stage pharma, closed a $76 million Series A financing to support its pipeline and open a global Philadelphia headquarters. The company will continue to operate its Jinan facility. KPB focuses on re-purposing approved medications with well-understood mechanisms to treat unmet needs. The company was founded by serial entrepreneur Dr. Zhen Hua Huang, who previously owned a China generics company. As part of the new funding, KBP hired Brian McVeigh, a GSK veteran, as CEO. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.